Share-based Payment Arrangement, Expense of scPharmaceuticals Inc. from 31 Dec 2016 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
scPharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Jun 2025.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $1,519,000, a 1.9% increase year-over-year.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $5,325,000, a 5.4% decline year-over-year.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,442,000, a 12% increase from 2023.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,856,000, a 71% increase from 2022.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,838,000, a 20% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

scPharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $5,325,000 $1,519,000 +$28,000 +1.9% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $5,297,000 $1,295,000 -$145,000 -10% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $5,442,000 $1,284,000 -$132,000 -9.3% 01 Oct 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
Q3 2024 $5,574,000 $1,227,000 -$54,000 -4.2% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $5,628,000 $1,491,000 +$312,000 +26% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $5,316,000 $1,440,000 +$460,000 +47% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $4,856,000 $1,416,000 +$679,000 +92% 01 Oct 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
Q3 2023 $4,177,000 $1,281,000 +$496,000 +63% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $3,681,000 $1,179,000 +$499,000 +73% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $3,182,000 $980,000 +$344,000 +54% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $2,838,000 $737,000 +$100,000 +16% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $2,738,000 $785,000 +$166,000 +27% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $2,572,000 $680,000 +$91,000 +15% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,481,000 $636,000 +$115,000 +22% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $2,366,000 $637,000 +$510,000 +402% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $1,856,000 $619,000 -$125,000 -17% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $1,981,000 $589,000 -$32,000 -5.2% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $2,013,000 $521,000 +$13,000 +2.6% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $2,000,000 $127,000 -$308,000 -71% 01 Oct 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
Q3 2020 $2,308,000 $744,000 +$411,000 +123% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $1,897,000 $621,000 +$295,000 +90% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $1,602,000 $508,000 +$153,000 +43% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $1,449,000 $435,000 -$18,000 -4% 01 Oct 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
Q3 2019 $1,467,000 $333,000 -$230,000 -41% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $1,697,000 $326,000 -$171,000 -34% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $1,868,000 $355,000 -$267,000 -43% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q4 2018 $2,135,000 $453,000 +$76,000 +20% 01 Oct 2018 31 Dec 2018 10-K 24 Mar 2020 2019 FY
Q3 2018 $2,059,000 $563,000 +$329,000 +141% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,730,000 $497,000 +$269,000 +118% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $1,461,000 $622,000 +$514,000 +476% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $947,000 $377,000 01 Oct 2017 31 Dec 2017 10-K 21 Mar 2019 2018 FY
Q3 2017 $234,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $228,000 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $108,000 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1

scPharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,442,000 +$586,000 +12% 01 Jan 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
2023 $4,856,000 +$2,018,000 +71% 01 Jan 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
2022 $2,838,000 +$472,000 +20% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $2,366,000 +$366,000 +18% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $2,000,000 +$551,000 +38% 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
2019 $1,449,000 -$686,000 -32% 01 Jan 2019 31 Dec 2019 10-K 23 Mar 2021 2020 FY
2018 $2,135,000 +$1,188,000 +125% 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2020 2019 FY
2017 $947,000 +$71,000 +8.1% 01 Jan 2017 31 Dec 2017 10-K 21 Mar 2019 2018 FY
2016 $876,000 01 Jan 2016 31 Dec 2016 10-K 21 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.